A cost-of-illness study estimating the direct cost per asthma exacerbation in Turkey
Authors:
- Sevim BavbekSBSevim Bavbek
- Dilşad MunganDMDilşad Mungan
- Haluk TürktaşHTHaluk Türktaş
- Zeynep MısırlıgilZMZeynep Mısırlıgil
- Bilun GemicioğluBGBilun Gemicioğlu
- 1 April 2011
- journal article
- research article
- Published by Elsevier in Respiratory Medicine
- Vol. 105 (4) , 541-548
Abstract
No abstract availableKeywords
Funding Information
- Astra-Zeneca Turkey
This publication has 31 references indexed in Scilit:
- Epidemiology of asthma exacerbationsJournal of Allergy and Clinical Immunology, 2008
- The economic consequences of asthma among adults in SwedenRespiratory Medicine, 2007
- Cost-effectiveness analysis of budesonide/formoterol compared with fluticasone in moderate-persistent asthmaRespiratory Medicine, 2006
- An international observational prospective study to determine the Cost Of Asthma eXacerbations (COAX)Respiratory Medicine, 2006
- Coste y manejo de una crisis asmática en el ámbito hospitalario de nuestro medio (estudio COAX en servicios hospitalarios)Archivos de Bronconeumología, 2005
- Asthma: prevalence and cost of illnessEuropean Respiratory Journal, 2005
- The global burden of asthma: executive summary of the GINA Dissemination Committee ReportAllergy, 2004
- The health economics of asthma and rhinitis. I. Assessing the economic impactJournal of Allergy and Clinical Immunology, 2001
- Trends in the cost of illness for asthma in the United States, 1985-1994Journal of Allergy and Clinical Immunology, 2000
- Risk factors and costs associated with an asthma attackThorax, 2000